Stockscreener 앱 받기
25.69
5.46%
1.33
시장 영업 전:
26.24
0.55
+2.14%
전일 마감가:
$24.36
열려 있는:
$24.605
하루 거래량:
23.68M
Relative Volume:
4.92
시가총액:
$2.89B
수익:
-
순이익/손실:
$-99.15M
주가수익비율:
-27.62
EPS:
-0.93
순현금흐름:
$-74.25M
1주 성능:
-37.75%
1개월 성능:
-19.74%
6개월 성능:
-18.78%
1년 성능:
-61.16%
1일 변동 폭
$24.53
$26.74
1주일 범위
$23.21
$42.23
52주 변동 폭
$18.92
$81.73
Viking Therapeutics Inc Stock (VKTX) Company Profile
명칭
Viking Therapeutics Inc
전화
858-704-4660
주소
9920 PACIFIC HEIGHTS BLVD, SUITE 350, SAN DIEGO, CA
VKTX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VKTX
Viking Therapeutics Inc
|
25.69 | 4.73B | 0 | -99.15M | -74.25M | -0.93 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.36 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
591.01 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
458.31 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.97 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
309.33 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Viking Therapeutics Inc Stock (VKTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-29 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-04-08 | 개시 | Goldman | Neutral |
| 2025-02-13 | 개시 | Scotiabank | Sector Outperform |
| 2025-02-07 | 개시 | Citigroup | Neutral |
| 2024-12-02 | 개시 | Piper Sandler | Overweight |
| 2024-11-22 | 개시 | B. Riley Securities | Buy |
| 2024-11-04 | 재확인 | H.C. Wainwright | Buy |
| 2024-09-11 | 개시 | JP Morgan | Overweight |
| 2024-06-27 | 개시 | Morgan Stanley | Overweight |
| 2024-05-16 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2024-03-26 | 재확인 | Oppenheimer | Outperform |
| 2024-03-07 | 개시 | Jefferies | Buy |
| 2024-02-28 | 재확인 | Oppenheimer | Outperform |
| 2023-05-31 | 재개 | ROTH MKM | Buy |
| 2023-03-28 | 재확인 | Maxim Group | Buy |
| 2023-03-17 | 개시 | Stifel | Buy |
| 2021-07-29 | 재개 | BTIG Research | Buy |
| 2021-05-25 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
| 2020-06-05 | 개시 | BMO Capital Markets | Outperform |
| 2020-05-05 | 개시 | Chardan Capital Markets | Buy |
| 2020-05-01 | 개시 | BTIG Research | Buy |
| 2019-07-16 | 개시 | Oppenheimer | Outperform |
| 2019-06-25 | 개시 | Stifel | Buy |
| 2019-03-29 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2019-03-14 | 재확인 | Maxim Group | Buy |
| 2019-02-22 | 개시 | SVB Leerink | Mkt Perform |
| 2018-12-12 | 개시 | B. Riley FBR | Buy |
| 2018-11-19 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2018-09-18 | 재확인 | H.C. Wainwright | Buy |
| 2018-09-18 | 재확인 | Maxim Group | Buy |
| 2018-09-18 | 재확인 | Raymond James | Outperform |
| 2018-07-20 | 개시 | SunTrust | Buy |
| 2018-06-28 | 개시 | Raymond James | Outperform |
| 2018-06-01 | 재확인 | Laidlaw | Buy |
| 2018-05-31 | 재확인 | Maxim Group | Buy |
| 2018-03-26 | 재개 | H.C. Wainwright | Buy |
| 2017-11-28 | 재확인 | Maxim Group | Buy |
| 2017-11-21 | 개시 | ROTH Capital | Buy |
모두보기
Viking Therapeutics Inc 주식(VKTX)의 최신 뉴스
Viking Therapeutics Stock: Panic Creates Opportunity (NASDAQ:VKTX) - Seeking Alpha
Viking Therapeutics' VK2735: Can a Dual-Acting Obesity Pill Navigate Tolerability and Competition to Win the Market? - AInvest
Viking Therapeutics' VK2735 Trial: A Cautionary Tale for Small Biotechs in the Obesity Drug Gold Rush - AInvest
Viking Therapeutics (VKTX) Slashes 42% on Huge Clinical Study Dropout Rate - MSN
Here's Why Viking Therapeutics Bounced Back Today - Yahoo Finance
Viking Therapeutics' VK2735: A Game-Changer in Oral Weight Management - AInvest
Under Pressure: Palantir and Viking Therapeutics Face Investor Scrutiny - FinancialContent
Viking Therapeutics' Stock Tanks on Mixed Data From Obesity Pill Study - Yahoo Finance
Viking Therapeutics Reports 6 Percent Weight Loss in Phase 1 Trial of Oral Drug VK2735 - geneonline.com
Viking Therapeutics: What's Happening With VKTX Stock? - Forbes
Wall Street Analysts Think Viking Therapeutics (VKTX) Is a Good Investment: Is It? - Yahoo Finance
How to Navigate Viking Therapeutics After Disappointing Data - TheStreet Pro
Is Viking Therapeutics A High-Risk High-Reward Biotech Play? - Trefis
Viking Therapeutics shorts gain $0.5B amid selloff: report - MSN
Viking Therapeutics stock maintains Strong Buy rating at Raymond James - Investing.com
Viking Therapeutics short sellers reap $521 million profit in one day amid selloff. - AInvest
Viking Therapeutics shorts gain $0.5B on selloff (VKTX:NASDAQ) - Seeking Alpha
Viking Therapeutics shares tumble after obesity drug trial disappoints - Proactive financial news
Viking Therapeutics' weight-loss pill disappoints in phase 2 - medwatch.com
Viking's 42% Plunge Splits Experts—A '$129 Strong Buy' Or 'Clearly Inferior' Drug? - Benzinga
Viking Therapeutics Rises as Phase 3 Trials and Oral Formulation Progress Accelerate - MSN
Viking Therapeutics Plunges 37% on Obesity Drug Trial Concerns - MSN
Viking Therapeutics Plummets as Oral Obesity Drug Trial Raises Tolerability Concerns - FinancialContent
Mizuho's Jared Holz talks Viking Therapeutics' massive stock drop on obesity pill data - MSN
Oral weight loss drug "crash"! Viking Therapeutics' stock price plummeted 42%, and short sellers made a profit of $521 million overnight. - 富途牛牛
Why Viking Therapeutics stock reaction to obesity pill data is wildly ‘overdone’ - Invezz
Viking Therapeutics Plunges 42.12% on $1.64 Billion Volume, Ranking 39th Despite Strong Trial Data Skepticism - AInvest
Viking Therapeutics Stock Plummets 42% on Clinical Trial Setback - AInvest
Viking Therapeutics Stock Plummets 42% on Weight Loss Drug Setback - AInvest
Viking Therapeutics (VKTX) Sees Record Stock Drop Amid Drug Trial Concerns - GuruFocus
Viking Therapeutics: Phase 2 Oral Obesity Data Affirms Bear Case, Downgrade To Sell (VKTX) - Seeking Alpha
Viking Therapeutics stock crashes after weight-loss pill trial shows high dropout rate - Yahoo Finance
Viking Therapeutics Shares Plunge Nearly 50% After Obesity Drug Trial Shows High Discontinuation Rates - geneonline.com
Intel, Home Depot, Palo Alto, Viking Therapeutics, Palantir, Medtronic, and More Movers - Barron's
Viking Therapeutics shares rise 1.52% after-hours as obesity pill shows promising weight loss results in Phase 2 trial. - AInvest
Stock Market Today: Home Depot, Intel, and Viking Therapeutics are on the move - TheStreet
Viking Therapeutics Crashes 42% On Mixed Results For Its Weight-Loss Pill - Investor's Business Daily
Viking Therapeutics stock plunges: Weight-loss pill trial disappoints - Yahoo Finance
Stock Movers: Intel, Viking Therapeutics, Home Depot - Bloomberg.com
Viking Therapeutics stock rises as Truist reiterates Buy on weight loss data By Investing.com - Investing.com South Africa
Viking Therapeutics Crashes Over 40% After Weight-Loss Drug Trial Sparks Safety Concerns - International Business Times UK
Viking Therapeutics weakness ‘overdone,’ says Leerink - TipRanks
Viking Obesity Pill Faces Steep Climb Against Lilly's Tirzepatide, Analyst Calls Downtrend Reaction 'Extreme' - Benzinga
Viking Therapeutics stock rating reiterated as Buy by Jefferies - Investing.com
Viking Therapeutics oral weight loss drug hits mark in mid-stage trial but disappoints investors - statnews.com
How does Viking’s oral obesity drug stand up to those of Eli Lilly and Novo? - Seeking Alpha
Viking Therapeutics Shorts Reap $514 Million as Stock Falls 40% - Bloomberg.com
Viking Therapeutics Shares Sink After Obesity Pill Data; Truist Says Sell-Off Overdone - MarketScreener
Viking Therapeutics’ VK2735: Promising Phase 2 Results Highlight Strong Market Potential and Commercial Viability - TipRanks
Stifel says buy Viking Therapeutics following ‘overreaction’ to Phase 2 outcome - TipRanks
Viking Therapeutics stock falls as market weighs Phase 2 weight loss data - Investing.com
Viking Therapeutics Inc (VKTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Viking Therapeutics Inc 주식 (VKTX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| ZANTE GREG | Chief Financial Officer |
Jul 03 '25 |
Sale |
27.76 |
4,266 |
118,428 |
168,660 |
| Mancini Marianna | Chief Operating Officer |
Jul 03 '25 |
Sale |
27.77 |
4,266 |
118,473 |
377,535 |
2.44%
0.09%
자본화:
|
볼륨(24시간):